JP2009509544A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009509544A5 JP2009509544A5 JP2008533689A JP2008533689A JP2009509544A5 JP 2009509544 A5 JP2009509544 A5 JP 2009509544A5 JP 2008533689 A JP2008533689 A JP 2008533689A JP 2008533689 A JP2008533689 A JP 2008533689A JP 2009509544 A5 JP2009509544 A5 JP 2009509544A5
- Authority
- JP
- Japan
- Prior art keywords
- promoter
- cell
- construct
- vector
- cis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 51
- 230000004927 fusion Effects 0.000 claims 39
- 230000001105 regulatory effect Effects 0.000 claims 38
- 239000003795 chemical substances by application Substances 0.000 claims 30
- 108091030071 RNAI Proteins 0.000 claims 29
- 230000009368 gene silencing by RNA Effects 0.000 claims 29
- 239000013598 vector Substances 0.000 claims 28
- 239000000203 mixture Substances 0.000 claims 26
- 230000014509 gene expression Effects 0.000 claims 25
- 108700039691 Genetic Promoter Regions Proteins 0.000 claims 24
- 108090000623 proteins and genes Proteins 0.000 claims 21
- 101710135281 DNA polymerase III PolC-type Proteins 0.000 claims 20
- 230000033228 biological regulation Effects 0.000 claims 17
- 230000000694 effects Effects 0.000 claims 15
- 238000000034 method Methods 0.000 claims 14
- 150000007523 nucleic acids Chemical class 0.000 claims 14
- 102000014450 RNA Polymerase III Human genes 0.000 claims 11
- 108010078067 RNA Polymerase III Proteins 0.000 claims 11
- 241001465754 Metazoa Species 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 9
- 102000039446 nucleic acids Human genes 0.000 claims 9
- 108091027967 Small hairpin RNA Proteins 0.000 claims 8
- 108020004459 Small interfering RNA Proteins 0.000 claims 8
- 230000005764 inhibitory process Effects 0.000 claims 8
- 239000004055 small Interfering RNA Substances 0.000 claims 8
- 230000001225 therapeutic effect Effects 0.000 claims 6
- 108091026890 Coding region Proteins 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000013612 plasmid Substances 0.000 claims 5
- 239000013603 viral vector Substances 0.000 claims 5
- 230000002068 genetic effect Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 210000004102 animal cell Anatomy 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 2
- 230000000052 comparative effect Effects 0.000 claims 2
- 229940011871 estrogen Drugs 0.000 claims 2
- 239000000262 estrogen Substances 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 230000009261 transgenic effect Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 241000238631 Hexapoda Species 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 230000022131 cell cycle Effects 0.000 claims 1
- 239000013626 chemical specie Substances 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 239000007972 injectable composition Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000013641 positive control Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000006335 response to radiation Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72256805P | 2005-10-01 | 2005-10-01 | |
| US60/722,568 | 2005-10-01 | ||
| PCT/US2006/038154 WO2007041350A2 (en) | 2005-10-01 | 2006-09-29 | Regulatable fusion promoters |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012219504A Division JP2012254098A (ja) | 2005-10-01 | 2012-10-01 | 調節可能な融合プロモーター |
| JP2015175115A Division JP6199934B2 (ja) | 2005-10-01 | 2015-09-04 | 調節可能な融合プロモーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009509544A JP2009509544A (ja) | 2009-03-12 |
| JP2009509544A5 true JP2009509544A5 (enExample) | 2010-11-18 |
| JP5976986B2 JP5976986B2 (ja) | 2016-08-24 |
Family
ID=37906746
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008533689A Expired - Fee Related JP5976986B2 (ja) | 2005-10-01 | 2006-09-29 | 調節可能な融合プロモーター |
| JP2012219504A Pending JP2012254098A (ja) | 2005-10-01 | 2012-10-01 | 調節可能な融合プロモーター |
| JP2015175115A Expired - Fee Related JP6199934B2 (ja) | 2005-10-01 | 2015-09-04 | 調節可能な融合プロモーター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012219504A Pending JP2012254098A (ja) | 2005-10-01 | 2012-10-01 | 調節可能な融合プロモーター |
| JP2015175115A Expired - Fee Related JP6199934B2 (ja) | 2005-10-01 | 2015-09-04 | 調節可能な融合プロモーター |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090053295A1 (enExample) |
| EP (2) | EP2386564B1 (enExample) |
| JP (3) | JP5976986B2 (enExample) |
| AU (1) | AU2006297112B2 (enExample) |
| CA (1) | CA2665080C (enExample) |
| WO (1) | WO2007041350A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7863251B2 (en) * | 2005-06-09 | 2011-01-04 | Agency For Science, Technology And Research | Hepatic stellate cell specific promoter and uses thereof |
| US20070299029A1 (en) * | 2005-06-09 | 2007-12-27 | Agency For Science, Technology And Research | Hepatic stellate cell specific promoter and uses thereof |
| AU2009293636A1 (en) * | 2008-09-22 | 2010-03-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the specific inhibition of gene expression by dsRNA possessing modifications |
| US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| CN102227503B (zh) * | 2008-09-26 | 2015-10-21 | 托卡根公司 | 重组载体 |
| AU2009336191B2 (en) * | 2008-12-18 | 2017-08-24 | Novo Nordisk A/S | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| WO2014066700A1 (en) | 2012-10-25 | 2014-05-01 | Tocagen Inc. | Retroviral vector with mini-promoter cassette |
| US11279949B2 (en) | 2015-09-04 | 2022-03-22 | Denovo Biopharma Llc | Recombinant vectors comprising 2A peptide |
| JP2021524467A (ja) * | 2018-05-23 | 2021-09-13 | メニスマート セラピューティクス， インコーポレイテッドＭａｎｙｓｍａｒｔ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 二重特異性ｔ細胞誘導体及びその使用 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5573933A (en) | 1987-04-14 | 1996-11-12 | Luminis Pty, Ltd. | Transgenic pigs |
| US5166320A (en) * | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| CA2098849C (en) * | 1990-12-20 | 2007-07-10 | Ralph R. Weichselbaum | Control of gene expression by ionizing radiation |
| US5922854A (en) | 1991-06-14 | 1999-07-13 | Kumar; Ramesh | Purifying Human Hemogloblin from transgenic pig red cells and plasmids containing pig globin nucleic acids |
| AU687743B2 (en) | 1992-06-12 | 1998-03-05 | Dnx Corporation | Production of human hemoglobin in transgenic pigs |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| FR2738842B1 (fr) * | 1995-09-15 | 1997-10-31 | Rhone Poulenc Rorer Sa | Molecule d'adn circulaire a origine de replication conditionnelle, leur procede de preparation et leur utilisation en therapie genique |
| US5874304A (en) * | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| US6818209B1 (en) | 1998-05-22 | 2004-11-16 | Oxford Biomedica (Uk) Limited | Retroviral delivery system |
| US6924123B2 (en) | 1996-10-29 | 2005-08-02 | Oxford Biomedica (Uk) Limited | Lentiviral LTR-deleted vector |
| DE19751587A1 (de) * | 1997-11-21 | 1999-07-29 | Hoechst Marion Roussel De Gmbh | Onkogen- oder virusgesteuerte Expressionssysteme |
| DE19756975A1 (de) * | 1997-12-20 | 1999-06-24 | Hoechst Marion Roussel De Gmbh | Bindungspartner für Inhibitoren von cyclinabhängigen Kinasen und ihre Verwendung zur Suche nach Inhibitoren, zur Diagnose oder zur Therapie einer Erkrankung |
| US6420335B1 (en) * | 1998-06-15 | 2002-07-16 | Dana Farber Cancer Institute, Inc. | Combination of radiotherapy and anti-angiogenic factors |
| DE19831420A1 (de) * | 1998-07-14 | 2000-01-20 | Hoechst Marion Roussel De Gmbh | Expressionssysteme enthaltend chimäre Promotoren mit Bindungsstellen für rekombinante Transkriptionsfaktoren |
| EP1165842A4 (en) | 1999-03-16 | 2004-07-07 | Dana Farber Cancer Inst Inc | LENTIVIRAL VECTOR SYSTEM FOR LARGE QUANTITY SCREENING |
| WO2000072886A1 (en) * | 1999-05-26 | 2000-12-07 | Dana-Farber Cancer Institute, Inc. | Episomally replicating lentiviral vectors |
| JP3704037B2 (ja) * | 1999-11-05 | 2005-10-05 | 独立行政法人産業技術総合研究所 | スライディング可能な機能性キメラ分子 |
| US6579522B1 (en) * | 2000-06-27 | 2003-06-17 | Genvec, Inc. | Replication deficient adenoviral TNF vector |
| JP3613576B2 (ja) * | 2000-10-30 | 2005-01-26 | 独立行政法人産業技術総合研究所 | 細胞内で高機能な核酸分子の選択方法 |
| AU2002345658A1 (en) * | 2001-06-13 | 2002-12-23 | Eastern Virginia Medical School | Methods for targeted expression of therapeutic nucleic acid |
| JP4745563B2 (ja) * | 2001-09-11 | 2011-08-10 | 一般財団法人 化学物質評価研究機構 | レポータープラスミド |
| GB0130955D0 (en) * | 2001-12-24 | 2002-02-13 | Cancer Res Ventures | Expression system |
| US6863884B2 (en) | 2002-05-01 | 2005-03-08 | Cell Genesys, Inc. | Pseudotyped retroviral vectors |
| US20050196862A1 (en) * | 2002-08-30 | 2005-09-08 | Wooddell Christine I. | DNA cassette for cellular expression of small RNA |
| US6799657B2 (en) * | 2002-10-02 | 2004-10-05 | Carrier Corporation | Absorptive/reactive muffler for variable speed compressors |
| US20040234504A1 (en) * | 2002-12-18 | 2004-11-25 | Verma Inder M. | Methods of inhibiting gene expression by RNA interference |
| ATE490321T1 (de) * | 2003-01-17 | 2010-12-15 | Max Planck Gesellschaft | Induzierbare sirna expressionskonstrukte zur gezielten genabschaltung |
| US20050013018A1 (en) | 2003-07-16 | 2005-01-20 | Alex Ning | Compact lens assembly |
| WO2005007877A2 (en) * | 2003-07-18 | 2005-01-27 | University Of Massachusetts | Regulatable promoters for synthesis of small hairpin rna |
| WO2005007875A2 (en) * | 2003-07-18 | 2005-01-27 | University Of Massachusetts | Enhanced promoters for synthesis of small hairpin rna |
| US20050089902A1 (en) * | 2003-09-02 | 2005-04-28 | The Scripps Research Institute | Methods and compositions for siRNA expression |
| US20050166272A1 (en) * | 2003-12-09 | 2005-07-28 | National Institute Of Advanced Industrial Science And Technology | Enhancement of RNAi activity through mutation |
| JP4753130B2 (ja) * | 2003-12-12 | 2011-08-24 | 独立行政法人産業技術総合研究所 | インターフェロン応答が軽減された長い干渉用二重鎖ｒｎａ |
| WO2005068630A1 (ja) * | 2003-12-16 | 2005-07-28 | National Institute Of Advanced Industrial Science And Technology | 干渉用二重鎖ｒｎａ |
| US20050164210A1 (en) * | 2004-01-23 | 2005-07-28 | Vivek Mittal | Regulated polymerase III expression systems and related methods |
| WO2005086896A2 (en) * | 2004-03-10 | 2005-09-22 | Ulrich Thomann | Delivery vectors for short interfering rna, micro-rna and antisense rna |
| WO2005112620A2 (en) * | 2004-05-18 | 2005-12-01 | Massachusetts Institute Of Technology | A cre-lox based method for conditional rna interference |
| US8008468B2 (en) * | 2005-02-16 | 2011-08-30 | Benitec, Inc. | RNAi expression constructs with liver-specific enhancer/promoter |
-
2006
- 2006-09-29 WO PCT/US2006/038154 patent/WO2007041350A2/en not_active Ceased
- 2006-09-29 AU AU2006297112A patent/AU2006297112B2/en not_active Ceased
- 2006-09-29 CA CA2665080A patent/CA2665080C/en not_active Expired - Fee Related
- 2006-09-29 EP EP11160708.1A patent/EP2386564B1/en not_active Not-in-force
- 2006-09-29 EP EP06815854A patent/EP1943265B1/en not_active Not-in-force
- 2006-09-29 JP JP2008533689A patent/JP5976986B2/ja not_active Expired - Fee Related
- 2006-09-29 US US12/088,921 patent/US20090053295A1/en not_active Abandoned
-
2012
- 2012-10-01 JP JP2012219504A patent/JP2012254098A/ja active Pending
-
2015
- 2015-09-04 JP JP2015175115A patent/JP6199934B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Meloni et al. | Local inhibition of microRNA-24 improves reparative angiogenesis and left ventricle remodeling and function in mice with myocardial infarction | |
| Li et al. | MicroRNA-214 suppresses gluconeogenesis by targeting activating transcriptional factor 4 | |
| ES2739804T3 (es) | Compuestos terapéuticos | |
| Wang et al. | Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice | |
| KR101706259B1 (ko) | 섬유증을 조절하는 마이크로-ｒｎａ 집단 및 이의 용도 | |
| Sakakibara et al. | Six homeoproteins and a linc-RNA at the fast MYH locus lock fast myofiber terminal phenotype | |
| KR20100057022A (ko) | 마이오신 발현 및 근섬유 동일성을 제어하는 마이크로-ｒｎａｓ | |
| KR20100099158A (ko) | 심근세포 생존과 심장 회복을 제어하는 ＭＩＲ-15 집단의 마이크로ＲＮＡｓ | |
| KR20090037968A (ko) | 베타-마이오신 중사슬의 발현을 활성화하는 마이크로-ｒｎａ의 동정 | |
| Ali et al. | miR-1 mediated suppression of Sorcin regulates myocardial contractility through modulation of Ca2+ signaling | |
| JP2012029693A5 (enExample) | ||
| Van Gestel et al. | shRNA-induced saturation of the microRNA pathway in the rat brain | |
| Yang et al. | Cardiac hypertrophy and dysfunction induced by overexpression of miR-214 in vivo | |
| Deng et al. | Transgenic overexpression of miR-133a in skeletal muscle | |
| Wang et al. | Identification and characterization of long non-coding RNAs in subcutaneous adipose tissue from castrated and intact full-sib pair Huainan male pigs | |
| CN111218451B (zh) | 一种提高猪肌肉量的方法 | |
| JP2009509544A5 (enExample) | ||
| Zhang et al. | Molecular mechanism for hypertensive renal disease: Differential regulation of chromogranin a expression at 3′-untranslated region polymorphism C+ 87T by MicroRNA-107 | |
| Teng et al. | Cardiac fibroblast miR‐27a may function as an endogenous anti‐fibrotic by negatively regulating Early Growth Response Protein 3 (EGR3) | |
| Tu et al. | In vitro and in vivo direct monitoring of miRNA-22 expression in isoproterenol-induced cardiac hypertrophy by bioluminescence imaging | |
| Lin et al. | RNA-based antipsoriatic gene therapy: an updated review focusing on evidence from animal models | |
| Ni et al. | Aberrant expression of miR-127, miR-21 and miR-16 in placentas of deceased cloned sheep | |
| Denovan-Wright et al. | Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo | |
| JP5522435B2 (ja) | Ｍｘｄ３遺伝子の発現阻害による肥満の抑制 | |
| CN103589730A (zh) | 一种抑制IRS1基因表达的shRNA及应用 |